Abstract
The 5-HT1A receptor has been extensively studied over the last two decades. There is a plethora of information describing its anatomical, physiological and biochemical roles in the brain. In addition, the development of selective pharmacological tools coupled with our understanding of psychiatric pathology has lead to multiple hypotheses for the therapeutic utility of 5-HT1A agents and in particular 5-HT1A receptor antagonists. Over the last decade it has been suggested that 5-HT1A receptor antagonists may have therapeutic utility in such diseases as depression, anxiety, drug and nicotine withdrawal as well as schizophrenia. However, a very compelling rationale has been developed for the therapeutic potential of 5-HT1A receptor antagonists in Alzheimers disease and potentially other diseases with associated cognitive dysfunction. Receptor blockade by a 5-HT1A receptor antagonist appears to enhance activation and signaling through heterosynaptic neuronal circuits known to be involved in cognitive p rocesses and, as such, represents a novel therapeutic approach to the treatment of cognitive deficits associated with Alzheimers disease and potentially other disorders with underlying cognitive dysfunction.
Keywords: 5-HT1A Receptor Antagonists, Alzheimers Disease
Current Pharmaceutical Design
Title: The Potential Utility of 5-HT1A Receptor Antagonists in the Treatment of Cognitive Dysfunction Associated with Alzheimers Disease
Volume: 8 Issue: 2
Author(s): L. E. Schechter, L. A. Dawson and J. A. Harder
Affiliation:
Keywords: 5-HT1A Receptor Antagonists, Alzheimers Disease
Abstract: The 5-HT1A receptor has been extensively studied over the last two decades. There is a plethora of information describing its anatomical, physiological and biochemical roles in the brain. In addition, the development of selective pharmacological tools coupled with our understanding of psychiatric pathology has lead to multiple hypotheses for the therapeutic utility of 5-HT1A agents and in particular 5-HT1A receptor antagonists. Over the last decade it has been suggested that 5-HT1A receptor antagonists may have therapeutic utility in such diseases as depression, anxiety, drug and nicotine withdrawal as well as schizophrenia. However, a very compelling rationale has been developed for the therapeutic potential of 5-HT1A receptor antagonists in Alzheimers disease and potentially other diseases with associated cognitive dysfunction. Receptor blockade by a 5-HT1A receptor antagonist appears to enhance activation and signaling through heterosynaptic neuronal circuits known to be involved in cognitive p rocesses and, as such, represents a novel therapeutic approach to the treatment of cognitive deficits associated with Alzheimers disease and potentially other disorders with underlying cognitive dysfunction.
Export Options
About this article
Cite this article as:
Schechter E. L., Dawson A. L. and Harder A. J., The Potential Utility of 5-HT1A Receptor Antagonists in the Treatment of Cognitive Dysfunction Associated with Alzheimers Disease, Current Pharmaceutical Design 2002; 8 (2) . https://dx.doi.org/10.2174/1381612023396483
DOI https://dx.doi.org/10.2174/1381612023396483 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diagnosis and Treatment of Common Sleep Disorders in Adolescence
Adolescent Psychiatry CD38 as a Regulator of Cellular NAD: A Novel Potential Pharmacological Target for Metabolic Conditions
Current Pharmaceutical Design Naturally Occurring and Synthetic Imidazoles: Their Chemistry and Their Biological Activities
Current Medicinal Chemistry Prolyl Oligopeptidase Structure and Dynamics
CNS & Neurological Disorders - Drug Targets Meet Our Editorial Board Member
Current Alzheimer Research Biomarkers of Major Depression Related to Serotonin Receptors
Current Psychiatry Reviews The Evolving Therapy of Rheumatic Diseases, The Future is Now
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Chemokines as Drug Targets in Type 1 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets Bioadhesive Films as Drug Delivery Systems
Drug Delivery Letters PET Imaging in Parkinsons Disease
Current Medical Imaging 2D & 3D-QSAR Study on Novel Piperidine and Piperazine Derivatives as Acetylcholinesterase Enzyme Inhibitors
Current Computer-Aided Drug Design Mechanisms of Resistance to Imatinib in CML Patients: A Paradigm for the Advantages and Pitfalls of Molecularly Targeted Therapy
Current Cancer Drug Targets Pathological Role of Advanced Glycation End Products (AGEs) and their Receptor Axis in Atrial Fibrillation
Mini-Reviews in Medicinal Chemistry Epigenetic Effects Mediated by Antiepileptic Drugs and their Potential Application
Current Neuropharmacology Cysteine-, Methionine- and Seleno-Cysteine-Proline Chimeras: Synthesis and Their Use in Peptidomimetics Design
Current Bioactive Compounds A New Interpretative Paradigm for Conformational Protein Diseases
Current Protein & Peptide Science Brain Permeable Nanoparticles
Recent Patents on CNS Drug Discovery (Discontinued) Hydroxytyrosol and Derivatives: Isolation, Synthesis, and Biological Properties
Current Organic Chemistry Smoking, Estradiol Metabolism and Hormone Replacement Therapy
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Secretoneurin: A New Player in Angiogenesis and Chemotaxis Linking Nerves, Blood Vessels and the Immune System
Current Protein & Peptide Science